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The management of inherited gastric cancer syndromes is a 
challenging field, with prophylactic total gastrectomy (PTG) 
the only effective preventive measure for at risk individuals. 
Germline mutations in CDH1, encoding E-cadherin, account 
for around 30% of cases of hereditary diffuse gastric cancer 
(HDGC). Individuals carrying a pathogenic mutation in 
CDH1 have a high lifetime risk of developing diffuse gastric 
cancer, estimated to be 70% in men and 56% in women (1). 
Current international consensus guidelines recommend that 
PTG should be offered to carriers of pathogenic mutations (1). 
Individuals electing to defer surgery should undergo annual 
endoscopy with multiple biopsies following the Cambridge 
protocol (1). Our current limited understanding of what 
triggers the progression from non-invasive to invasive signet 
ring adenocarcinoma in this setting means that early surgery 
remains the chosen course of action for many.
The decision to proceed to PTG is life-changing and 
often a source of significant anxiety for a patient and their 
family. The recent study by Muir et al. is an examination of 
the issues surrounding quality of life, surgery and decision 
making in a population at risk of HDGC (2). Eighteen 
patients who were offered PTG were recruited to a 
longitudinal questionnaire study extending up to 24 months 
post-PTG. Thirteen patients proceeded to surgery, and the 
five who declined or deferred surgery completed baseline 
questionnaires. Patients completed standard quality of life 
questionnaires (EORTC QLQ-C30 and STO22) and this 
was combined with assessments of body image, regret, 
decisional conflict and psychological symptoms.
The inclusion of an assessment of decisional conflict 
is welcome given the magnitude of the decision and it is 
interesting that most patients expressed little regret. In a 
qualitative interview study about the factors influencing 
decision to undergo PTG there appear to be many factors 
influencing the decision making process including the 
perception of risk and perceptions of life post-surgery (3).
Interestingly, there were no long-term psychological 
or body image consequences of PTG in this cohort. 
However, chronic low-severity health related quality 
of life (HRQL) limiting symptoms were common. 
Unsurprisingly, at 2–4 weeks post-gastrectomy, significant 
reductions in global HRQL, role and social functioning, and 
symptom scores, were commonly observed. Intriguingly, 
global HRQL and role/social functioning subscales 
returned to baseline 12 months following PTG, prior to 
dropping once again at 24 months, although this analysis is 
based on only three patients and may not be generalizable. 
It would be interesting to know the correlation between 
body image and global QOL scores.
Post-gastrectomy symptoms, as reported by the EORTC 
STO22, were common, with more than half of patients 
experiencing reflux, eating restriction and dry mouth. 
Health-based anxiety was not reduced by surgery, reflecting 
the complex balance of cancer risk versus post-gastrectomy 
difficulties for this patient group. Despite the early 
prevalence of symptoms and reduced quality of life, only 
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half of participants expressed regret about their decision to 
proceed to PTG in the immediate post-operative period, 
which reduced over subsequent assessments.
The findings of Muir et al. reflect those published by 
Worster et al. from Cambridge, UK (4), who demonstrated 
good recovery of physical functioning and HRQL at 12 
months post PTG despite ongoing symptoms. Interestingly, 
in the cohort studied by Worster, 44% complained of body 
image concerns at 12 months and it may be relevant that 
this cohort had a greater proportion of men than this study 
by Muir et al. which comprised mainly women (11 women 
and 2 men) who proceeded to surgery. In a qualitative 
interview study age was also shown to impact on recovery 
time, with younger patients reporting faster recovery (5).
Gastrectomy is a significant undertaking, with infrequent 
but major short-term risks and uncertain long-term 
consequences. There is very limited data on the long-term 
outcomes of gastrectomy in young people. Comparisons 
can be drawn with the long-term outcomes of surgical 
treatment of peptic ulcer disease; however this has not been 
commonplace for 40 years. Patient cohorts undergoing 
gastrectomy for invasive cancer tend to be older and, until 
recent improvements in oncological therapy, had a poor 
long-term prognosis (6).
A major  and pers i s t ing  consequence  of  upper 
gastrointestinal surgery is the poorly named “dumping 
syndrome”. Initially described in 1913, it encompasses a 
loosely connected constellation of symptoms experienced after 
meals, with early symptoms being predominantly vasomotor 
and late symptoms related to reactive hypoglycaemia (7,8). 
Over 50% of 269 post-total gastrectomy patients complained 
of some dumping symptoms in a large Japanese study (9). 
Whilst dumping explains many of the specific symptoms 
in Muir’s study, pathophysiological understanding of this 
syndrome is poor. Assuming that similar physiological 
mechanisms underpin the beneficial metabolic effects of 
bariatric surgery and the detrimental effects of gastric resection 
in lean patients, there are potential roles for altered bile acid, 
gut hormone and microbiome profiles (10-12). An improved 
understanding of the metabolic sequelae of gastrectomy 
may allow better physiological characterisation of dumping 
symptoms and more specific treatments than dietary advice, 
acarbose or somatostatin analogues. An exciting prospect 
is the development of glucagon like peptide 1 (GLP-1) 
antagonists (13).
Weight loss is a consistent outcome of gastrectomy and 
the extent of nutritional compromise appears to directly 
impact on quality of life (14). Nutritional support and loss of 
weight were key factors mentioned in open questioning by 
Muir et al. (2). A recent study from Dublin demonstrated 
a high incidence of pancreatic exocrine insufficiency, 
small intestinal bacterial overgrowth and fat soluble 
vitamin deficiency in 15 patients’ post-gastrectomy (15). 
In association with post-prandial dumping symptoms, 
these represent common but potentially treatable causes of 
significant weight loss after PTG.
One approach that has potential to reduce gastrointestinal 
symptoms is preservation of the vagus at the time of 
gastrectomy. A recently published randomised controlled trial 
of vagus preserving versus conventional distal gastrectomy, 
including 163 patients, demonstrated reduced diarrhoea 
and appetite loss at 12 months post-surgery (16). In our 
experience, it is possible to preserve the posterior vagus nerve 
while performing a PTG with adequate oncological clearance 
for a T1 signet ring adenocarcinoma.
It is unclear whether PTG in early adult life results in 
long-term nutritional consequences beyond weight loss. 
Patients undergoing Roux-en-Y gastric bypass (RYGB) 
for obesity, a similar operation to PTG in terms of enteric 
reconstruction, are recognised to be at risk of a range of 
micronutrient deficiencies (17). In a study by Adachi et al., 
59 patients of mean age 64 underwent bone mineral density 
assessment greater than 5 years after gastrectomy for cancer: 
71% of women, and 18% of men, were found to have bone 
mineral density measurements consistent with a diagnosis of 
osteoporosis (18). At present, there is insufficient evidence 
to say whether micronutrient deficiency will become a 
problem after PTG but it is reasonable to expect some 
degree of vitamin and mineral malabsorption in this patient 
group.
In conclusion, the study by Muir et al. is an important 
recognition of the wide-ranging psychological and quality 
of life issues affecting the small, but important subgroup 
of patients undergoing gastrectomy when otherwise fit and 
healthy (2). Global HRQL appears to return to baseline 
within 1 year of surgery, which is encouraging; however 
the chronic nature of gastrointestinal symptoms, persistent 
weight loss and uncertainty over long-term nutritional 
deficiencies represents a burden in the post-PTG patient 
group, perhaps reflected in their persisting health-related 
anxiety. Patients with CDH1 mutation advised to have risk-
reducing gastrectomy require cautious genetic and surgical 
counselling, including discussion of the long-term post-
PTG uncertainties to aid them in their decision making. 
Contact with other patients who have been through 
this process can be very useful in our experience. Life-
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long surgical and nutritional follow-up should monitor 
for treatable complications of gastrectomy as well as late 
presenting micronutrient deficiencies. In view of the rarity 
of HDGC it is important that the data is collected across 
multiple centres with long-term follow-up so that we can 
optimise the management for these individuals.
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